Advert - Janssen

• Date posted
  01 November 2016
• Sanction
  Advertisement,
• Case number/s
  AUTH/2871/8/16 - Voluntary admission by Janssen

For material sent by Janssen Europe to UK health professionals that promoted Stelara (ustekinumab) for an unlicensed indication and failing to certify such material, Janssen voluntarily admitted breaches of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.

Clause 3.2 - Promoting a medicine in a manner inconsistent with its summary of product characteristics.

Clause 9.1 - Failing to maintain high standards.

Clause 14.1 - Failing to certify promotional material.

The full case report was published in the PMCPA November 2016 Code of Practice Review and it is available at www.pmcpa.org.uk.